NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
Clinical Trials
4 trialsNCT05650476 2025-06-12
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Pfizer
Available
NCT05491928 2022-09-01
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Matrix Biomed, Inc.
Available
NCT03206931 2021-09-16
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Bayer
No longer available